Your browser doesn't support javascript.
loading
Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis.
Lau, Alexander Y; Lui, Grace C Y; Chan, Ka-Pang; Au, Cheryl; Mok, Vincent C T; Ziemssen, Tjalf.
Afiliação
  • Lau AY; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China. Electronic address: alexlau@cuhk.edu.hk.
  • Lui GCY; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China; Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Chan KP; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Au C; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Mok VCT; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Ziemssen T; Department of Neurology, Center of Clinical Neuroscience, Carl Gustav Carus University Clinic, University Hospital of Dresden, Dresden, Germany.
Mult Scler Relat Disord ; 38: 101503, 2020 Feb.
Article em En | MEDLINE | ID: mdl-31743846
ABSTRACT
Pneumocystis jirovecii pneumonia (PJP) is a known risk in patients with chronic lymphocytic leukemia treated with alemtuzumab (Campath®). However, no recommendation for PJP prophylaxis for alemtuzumab use in multiple sclerosis (Lemtrada®) and no known associated PJP has been reported to date. We report a patient who developed PJP two months after receiving the first course of Lemtrada, and fully recovered after receiving cotrimoxazole treatment. We should remain vigilant of opportunistic infections in patients who develop pneumonitis and evaluate the need for PJP prophylaxis during Lemtrada treatment.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia por Pneumocystis / Infecções Oportunistas / Esclerose Múltipla Recidivante-Remitente / Alemtuzumab / Fatores Imunológicos Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia por Pneumocystis / Infecções Oportunistas / Esclerose Múltipla Recidivante-Remitente / Alemtuzumab / Fatores Imunológicos Idioma: En Ano de publicação: 2020 Tipo de documento: Article